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Introduction
Obesity, which is an important risk factor for serious
chronic illnesses such as insulin resistance, type 2 dia-
betes, and heart disease is caused by an imbalance
between energy intake and energy expenditure. There
are numerous factors influencing whole-body energy
balance, including neural and hormonal signals, which,
when altered could result in obesity. It is becoming
increasingly evident that the central nervous system,
particularly the hypothalamus, plays a critical role in
integrating these signals to regulate energy balance and
that neuropeptide Y (NPY) is an important neuro-
modulator in this system (1, 2).
NPY is widely distributed throughout the brain (3).
However, most of the metabolic actions of NPY
appear to be mediated through defined hypothalam-
ic nuclei, including the arcuate nucleus (Arc) where
numerous NPY-containing neurons originate, the
paraventricular nucleus (PVN), where many NPY-
containing arcuate neuron terminals and NPY-bind-
ing sites are located, and the ventromedial hypothal-
amic (VMH) nucleus, which has been referred to as
“the satiety center” (3, 4). NPY is the most potent
orexigenic agent known (5, 6) and can also cause
changes in circulating hormone levels (7). Chronic
intracerebroventricular (icv) administration of NPY
results in hyperphagia, hyperinsulinemia, insulin
resistance, and obesity (8–10). Lesions of the VMH in
rodents also cause multiple changes in metabolic sta-
tus, including hyperphagia, hyperglycemia, and
hyperinsulinemia (11). Interestingly, injection of
NPY directly into the VMH significantly increases
food intake (12), and NPY-induced feeding is
enhanced in VMH-lesioned rats (13). These data sug-
gest the VMH may also be a site of action for NPY in
the development of obesity; however, the mecha-
nisms by which NPY is involved in each aspect of cen-
tral energy regulation remain to be defined.
Much research has focused on which of the 5 NPY-
receptor subtypes cloned so far (Y1, Y2, Y4, Y5, and the
y6) (14) might mediate the potent NPY-induced
feeding response. Several lines of evidence point to
the Y1- and/or Y5-receptor subtypes being the most
likely candidates for such an action (15–19). In addi-
tion, our previous studies investigating the mRNA
expression of all known Y receptors in the rat brain
also show clearly that both Y1- and Y5-receptor sub-
type mRNAs are expressed in areas pivotal in regu-
lating energy balance (20).
Glucocorticoid hormones play a critical role in
energy balance and also appear to mediate at least
some of their actions through the central NPY axis
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Chronic central administration of neuropeptide Y (NPY) causes hyperphagia, hyperinsulinemia,
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but this effect was completely absent in ADX rats in which basal plasma insulin levels were also
lower than controls. In addition, ADX significantly reduced the number of neurons expressing
NPY receptor Y1 and Y5 mRNAs in the ventromedial hypothalamus (VMH), without affecting Y1-
or Y5-mRNA expression in the paraventricular hypothalamus or the arcuate nucleus. These data
indicate that glucocorticoids are necessary for acute NPY-mediated insulin release and suggest
that the mechanisms involve glucocorticoid regulation of Y1 and Y5 receptors specifically with-
in the VMH nucleus.
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(21). In rats, excessive corticosterone promotes body
fat gain (22) and hyperinsulinemia (23) and also
increases NPY synthesis and Y1-receptor mRNA
expression, at least within the Arc (24, 25). Converse-
ly, removal of glucocorticoids by adrenalectomy
(ADX) reduces hyperphagia and body weight of obese
(fa/fa) rats (26), abolishes obesity induced by VMH
lesions (27), and prevents obesity induced by chron-
ic central NPY infusion in normal rats (28). However,
it has been reported that ADX does not alter Y1-
receptor mRNA expression in the Arc (24). Glucocor-
ticoid-receptor immunoreactivity is found within the
rat central nervous system, including the Arc, VMH,
and PVN (29). Many of these receptors are expressed
at the nucleus of NPY-containing, endocrine-related
neurons and coexist in regions containing high NPY-
receptor density (30).
Taken together, these observations indicate that
glucocorticoids have a regulatory role in long-term
central NPY signaling. However, it is not known what
regulatory role, if any, glucocorticoid hormones have
in the effects of acute, central administration of NPY
and how these actions relate to NPY-receptor expres-
sion. Therefore, we have examined the effects of ADX
on acute icv NPY-stimulated food intake and insulin
release in rats. Furthermore, we have analysed the
effects of ADX on Y1- and Y5-receptor mRNA expres-
sion within specific brain regions reported to regu-
late food intake and energy balance (Arc, PVN, and
VMH), using subtype-specific riboprobes and
employing a uniform technique of in situ hybridiza-
tion histochemistry. The results show that ADX
reduces basal plasma insulin levels, abolishes NPY-
induced insulin release, and significantly decreases
Y1- and Y5-receptor mRNA expression selectively
within the VMH. These data suggest that glucocorti-
coids regulate NPY-induced insulin release and NPY
signaling within the VMH of the hypothalamus.
Methods
Animals and surgical procedures
All procedures were approved by the Animal Experi-
mentation Ethics Committee (Garvan Institute and St.
Vincent’s Hospital, Sydney, Australia) and were in
accordance with the National Health and Medical
Research Council of Australia (NHMRC) guidelines on
animal experimentation.
Male Wistar rats (275–350 g) were housed under
standard lighting conditions (6:00 am to 6:00 pm)
with chow and water available ad libitum. Under keta-
mine (60 mg/kg; Parke Davis, Caringbah, Australia)
and xylazine (10 mg/kg; Bayer AG, Leverkusen,
Switzerland) anesthesia, a 22-gauge guide cannula
(Plastics One, Roanoke, Virginia, USA) was positioned
and fixed in the right lateral ventricle (icv) using a
stereotaxic surgical table and coordinates obtained
from a rat brain atlas (31). A cannula for blood sam-
pling was inserted into the jugular vein and routed out
through a small incision on the back between the
shoulders. It was plugged with polyvinylpyrrolidone
(PVP) in heparin saline to prevent clotting and leaking.
The rats were allowed to recover for at least 7 days.
After this recovery period, rats were tested for correct
cannula placement by a 4-hour feeding study after
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Figure 1
The effect of adrenalectomy on NPY-induced food intake in rats.
Rats received an acute injection of 1 m g NPY (icv), and cumulative
food intake was monitored over the next 4 hours. In a second set of
experiments NPY (5 m g) was injected icv and blood sampled for 2
hours without food being available. After 2 hours, food was pre-
sented to the rats and food intake monitored over the subsequent
hour. Results are expressed as the mean ± SE. Black bars represent
sham-operated NPY-injected rats (n = 12), and gray bars represent
ADX NPY-injected rats (n = 7).
Figure 2
Plasma corticosterone concentration after acute NPY injection in
normal, atropine-treated, and ADX rats. Plasma corticosterone was
measured after icv injection of vehicle or NPY (5 m g) in normal,
atropine-treated (1 mg/kg intravenously) or ADX rats as described
in Methods. Results are shown as the mean ± SE for 5–7 animals
per group. Filled squares represent vehicle-injected rats, filled dia-
monds represent NPY-injected rats, open triangles represent
atropine-treated NPY-injected rats, and open circles represent NPY-
injected ADX rats. NPY-injected normal rats and NPY-injected
atropine-treated rats had significantly higher corticosterone release
(P < 0.0001) than vehicle-injected normal rats or NPY-injected ADX
rats as assessed by repeated measures ANOVA.
acute icv NPY injection (5 m g). A subgroup of the rats
with significant food consumption after icv NPY were
reanesthetized, and both adrenal glands were surgi-
cally removed (ADX). Rats were given 0.9% saline in
their drinking water to maintain electrolyte balance.
Rats were handled and monitored daily to minimize
any stress during the experiments, which were per-
formed 8–10 days after the second surgical procedure.
ADX rats maintained normal food intake and body
weight gain after the surgical procedures and were
healthy in appearance and behavior.
Injection of compounds
NPY (Auspep Pty. Ltd., Melbourne, Australia) was
dissolved in 0.9% saline and injected as 5- m g and 1-
m g doses in a volume of 5 m L. Icv injections were per-
formed using a 28-gauge injection cannula (Plastics
One) connected to a Hamilton-1801RN 10- m L
syringe through Silastic tubing. Atropine methyl
nitrate (Sigma Chemical Co., St. Louis, Missouri,
USA) was given as a bolus (1 mg/kg) through the
jugular catheter 20 minutes before the icv adminis-
tration of NPY.
Experimental design
Measurement of food intake. On the morning of the exper-
iment, rats were placed in individual cages with access
to drinking water and allowed to acclimatize for about
1 hour. ADX and control rats were given an icv injec-
tion of NPY (1 m g) and returned to their cages with ad
libitum access to food and water. Food intake was
measured at 1, 2, and 4 hours after injection. Other
groups of sham and ADX rats were treated with vehicle
(icv 5 m L 0.9% saline) for comparison.
Blood sampling procedure. Rats were placed in indi-
vidual cages with access to water, and Silastic tubing
was connected to the in-dwelling jugular cannula for
blood sampling. After a 60- to 90-minute acclimati-
zation period, two basal blood samples were taken
approximately 15 minutes apart. Rats were removed
from the cages and injected with NPY (5 m g/5 m L
over 30 seconds) and returned to their cages for
blood sampling. Control experiments were per-
formed with icv injection of vehicle (5 m L 0.9%
saline). Two additional groups of animals were given
a bolus injection of a muscarinic receptor blocker (1
mg/kg atropine methyl nitrate ) 20 minutes before
icv NPY or saline injection to assess the role of the
parasympathetic nervous system in any hormonal
responses to the administration of NPY. Blood sam-
ples (300 m L) were collected at regular intervals for 2
hours after icv injection. The plasma was separated
by centrifugation, placed on ice, and plasma glucose
determined before storing at –20°C for further
assays. The red cells were resuspended in heparin
saline and returned to each rat. Food was presented
2 hours after icv injection of NPY or vehicle, and
intake was measured over the next hour to confirm
efficacy of the NPY injection.
Plasma measurements. Plasma glucose was measured
using a YSI 2300 STAT Plus Glucose & L-Lactate
Analyzer (Yellow Springs Instrument Co. Inc., Yellow
Springs, Colorado, USA). Plasma insulin and leptin
were measured using radioimmunoassay kits sup-
plied by Linco Research, Inc. (St. Charles, Missouri,
USA). Plasma corticosterone was measured using a
ImmuChem Double Antibody Corticosterone RIA
Kit for rats and mice (ICN Biomedicals Inc., Costa
Mesa, California, USA).
In situ hybridization histochemistry
In situ hybridization was essentially carried out as
described previously, at a hybridization temperature
of 50°C, using 200 ng/mL each of 11digoxigenin-
UTP–labeled riboprobe (20).
Data analysis. Regions containing positive
hybridization (dark brown/indigo color precipitate
deposit showing a halo pattern in the cytoplasm sur-
rounding a clearly visible nucleus) were identified
and mapped with the aid of a rat brain atlas (31).
The numbers of positively expressing cell bodies
were counted within the right and left PVN and Arc
and over a standard area for each VMH (n = 8 brain
sections each from 3 ADX and 3 control rats). No
detailed distinctions were made between subdivi-
sions within these nuclei. The levels of receptor-sub-
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Figure 3
Plasma insulin concentration after acute NPY injection in
normal, atropine-treated, and ADX rats. Plasma insulin was
measured in the same plasma samples as those used to gen-
erate Figure 2. Results are shown as the mean ± SE for 5–7
animals per group. (a) The effect of ADX on basal plasma
insulin (AP < 0.05). (b) The change in plasma insulin after icv
infusion of vehicle or NPY. Filled squares represent vehicle-
infused rats, filled diamonds represent NPY-injected rats,
open triangles represent atropine-treated NPY-injected rats,
and open circles represent NPY-injected ADX rats. NPY-
injected normal rats had significantly higher insulin release
(P < 0.0001) than vehicle-injected normal rats, NPY-injected
atropine-treated normal rats, or NPY-injected ADX rats as
assessed by repeated measures ANOVA.
type mRNA signal detected within these specific
hypothalamic areas were compared in control and
ADX rat brain sections obtained under the same
assay conditions, and high-power photomicrographs
were taken. Adjacent sections were counterstained
with hematoxylin/eosin to confirm morphological
identification of these hypothalamic areas.
Statistical analysis. Data are expressed as mean – SE,
either as raw data or change from baseline conditions.
Repeated measures ANOVA with relevant post-hoc
analysis was used to determine significant differences
between treatment groups, and unpaired t tests were
used to determine the significant difference for the in
situ hybridization results. A probability less than 0.05
was considered to be statistically different.
Results
Effects of ADX on NPY-induced feeding. An acute icv injec-
tion of NPY (1 m g) stimulated food intake to a similar
degree in both ADX and control rats at 1, 2, and 4
hours after NPY injection (Figure 1). When food was
presented to animals 2 hours after administration of
5 m g NPY and blood sampling, the food intake of con-
trol and ADX rats was also not significantly different
(Figure 1). Both sham and ADX animals injected with
saline vehicle icv consumed less than 1 g of food over
the 4-hour period, and there was no effect of ADX on
the spontaneous overnight food intake of the rats
(data not shown).
Effect of ADX on NPY-induced changes in plasma hor-
mones in the absence of feeding. In control rats without
access to food during the experiment, acute icv injec-
tion of vehicle (5 m L 0.9% saline) caused a significant
rise in plasma corticosterone, which returned to basal
levels after 60 minutes (Figure 2). This response was
similar if the rats were handled without any icv injec-
tion (data not shown) and occurred despite the fact
that all rats were handled on a daily basis to reduce
stress. Injection of 5 m g NPY (icv) produced a further
increase in plasma corticosterone levels compared
with vehicle injection (P < 0.05), and corticosterone
remained elevated for at least 2 hours after NPY injec-
tion (Figure 2). Blockade of muscarinic receptors with
atropine had no effect on the NPY-induced increase
in corticosterone levels, indicating that the effect of
icv NPY administration on corticosterone release was
not mediated through the parasympathetic nervous
system and the vagus nerve (Figure 2). As expected, in
ADX rats there was no increase in corticosterone lev-
els after acute icv injection of NPY.
Acute icv injection of NPY (5 m g) also caused a sig-
nificant increase in plasma insulin levels compared
with vehicle (P < 0.05), and insulin remained elevat-
ed for 90 minutes (Figure 3). Treatment of normal
rats with an intravenous bolus of a muscarinic recep-
tor blocker (atropine) 20 minutes before icv NPY
administration reduced the effect of NPY injection
on insulin release to a level that was not significant-
ly different from that of vehicle administration.
Atropine had no significant effect in vehicle-injected
rats. This indicates that the effect of central NPY
administration on insulin release is mediated by an
increase in parasympathetic nervous system activity
through vagal innervation of the pancreas. ADX rats
had significantly reduced basal plasma insulin levels
compared with controls (22.3 – 4.7 and 41.3 – 4.7
m U/mL, respectively; P < 0.05, see Figure 3a), and
there was no significant increase above basal levels
after acute NPY injection in ADX rats (Figure 3). The
differences in insulin were not due to differences in
plasma glucose levels, which were similar in the con-
trol and ADX rats and did not change after acute
NPY injection (P < 0.42; data not shown). Circulating
leptin was significantly decreased in ADX rats com-
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Figure 4
Photomicrograph of expression of Y1-receptor mRNA within hypothalamic nuclei of normal and ADX rats. Specific mRNA was detected by
in situ hybridization of serial sections of sham-operated and ADX rats as described in Methods. (a, c, and e) PVN, VMH, and Arc of normal
brains. (b, d, and f) PVN, VMH, and Arc of ADX rats. (g and h) Sense controls. The inset shows the schematic of the regions photographed.
Positive signals are defined as a color precipitate diffused around the nucleus (arrows). Scale bar = 100 m m.
pared with controls (1.6 ± 0.2 and 3.6 ± 0.4 ng/mL,
respectively) but there was no change in these levels
with acute injection of NPY (data not shown).
Y1- and Y5-receptor mRNA expression. Nonradioactive
in situ hybridization employing rat Y1- and Y5-specif-
ic riboprobes was used to determine possible changes
in Y-receptor expression after ADX. No cross-reactiv-
ity occurred when each receptor-specific riboprobe
was hybridized under conditions identical to those
used for in situ hybridization against vector con-
structs for each of the other known Y-receptor sub-
types. This result was not surprising given the very
low sequence identity of the different Y-receptor sub-
types (14). Furthermore, neither of the correspon-
ding sense riboprobes used under the same assay
conditions showed specific hybridization (Figures 4,
g and h, and Figure 5, g and h).
In the PVN, VMH, and Arc of control rats there was
approximately twice the number of neurons express-
ing Y1-receptor mRNA as those expressing Y5-receptor
mRNA (Figures 4, 5, and 6). These values confirm
those reported previously by our group using similar
hybridization techniques (20) and are comparable
with other published data, at least for Y1 mRNA
expression levels within normal Arc using a different
technique of in situ hybridization (32). Bilateral ADX
caused a significant reduction in the number of neu-
rons expressing Y1- (by up to 80%; P < 0.01) and Y5- (by
50%; P < 0.01) receptor mRNA within the VMH (Fig-
ures 4d, 5d, and 6). However, ADX did not signifi-
cantly change the numbers of neurons expressing Y1-
and/or Y5-receptor mRNA within the PVN or the Arc.
Discussion
Chronic icv infusion of NPY induces hyperphagia,
hyperinsulinemia, and insulin resistance in rats, and
these effects are blocked by previous ADX (28). In the
current study we demonstrate that ADX also abolish-
es the insulin release caused by an acute icv injection
of NPY and that this is associated with significantly
reduced Y1- and Y5-receptor mRNA expression specif-
ically within the VMH. These experiments imply that
glucocorticoids are necessary for icv NPY to stimulate
insulin release and suggest that glucocorticoids man-
ifest this regulatory role through alterations in Y1- and
Y5-receptor expression in the VMH.
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Figure 5
Photomicrograph of expression of Y5-receptor mRNA within hypothalamic nuclei of normal and ADX rats. Specific mRNA was detected by
in situ hybridization of serial sections of sham-operated and ADX rats as described in Methods. (a, c, and e) PVN, VMH, and Arc of normal
brains. (b, d, and f) PVN, VMH, and Arc of ADX rats. (g and h) Sense controls. The inset shows the schematic of the regions photographed.
Positive signals are defined as a color precipitate diffused around the nucleus (arrows). Scale bar = 100 m m.
Figure 6
Quantification of expression of Y1- and Y5-receptor
mRNA within hypothalamic nuclei. The number of
cell bodies staining for Y1- and Y5-receptor mRNA
was quantified as described in Methods. (a) The
number of cells showing hybridization for Y1-recep-
tor mRNA in the PVN, the VMH, and the Arc. (b)
The number of cells showing hybridization for Y5
mRNA in the same regions of the hypothalamus.
Plotted data represent the mean ± SE for determi-
nations from 3 separate control and ADX animals.
AP < 0.001, unpaired t-test.
Interestingly, in this study ADX rats showed no sig-
nificant alteration in the feeding response to acute NPY
injection. Therefore, it was not surprising that these
ADX rats also showed no change in expression of Y1-
and Y5-receptor mRNA (the proposed NPY feeding
receptors) within the PVN. There are contradictory
reports in the literature regarding the effects of ADX
on NPY-induced food intake. Some studies show that
food intake measured 1 hour after direct NPY admin-
istration into the PVN was partially attenuated by ADX
and was restored by corticosterone treatment (33, 34).
However, in agreement with our results, others report
that ADX had no significant effect on food intake in
rats during 2 hours of NPY infusion (35) or 2 hours
after acute icv NPY administration (36).
The fact that we found no change in the expression
of Y1- and Y5-receptor mRNA levels in the PVN and Arc
indicates that glucocorticoids are not essential for basal
regulation of Y1- and Y5-receptor mRNAs within these
areas. Our findings are in agreement with and further
extend previous studies, showing that glucocorticoids
are not essential for the regulation of Y1-receptor
mRNA in the Arc (24), and that ADX does not alter 125I-
PYY–specific binding in the Arc or PVN (25).
The current study, we believe, is the first to demonstrate
that ADX alters Y1- and Y5-receptor mRNA expression in
the VMH. A role for the VMH in insulin secretion and
adrenocortical regulation has been proposed previously
(37), but the mechanisms whereby glucocorticoids may
mediate the effects we observe on Y1- and Y5-receptor
mRNAs in the VMH are unknown. These effects could be
a direct action of glucocorticoids as glucocorticoid-recep-
tor immunoreactivity is widely distributed throughout
the rat forebrain, including the VMH (29). In addition,
the Y1-receptor gene is known to contain a putative glu-
cocorticoid response element (38), and it has been report-
ed that supplemental corticosterone treatment to ADX
rats increases NPY receptor–binding sites and Y1-recep-
tor mRNA levels within discrete hypothalamic nuclei (24,
25). It should be noted that other response elements may
also be involved in tissue-specific Y-receptor regulation
(38) and that changes in mRNA levels do not necessarily
equate to changes in the amount of receptor protein (39).
However, these findings do link ADX-induced effects on
Y-receptor expression in the VMH with alterations in the
insulinemic response to exogenous NPY, indicating that
these mRNA changes may indeed be of physiological sig-
nificance. Studies involving replacement of glucocorti-
coids and restoration of Y1-and Y5-receptor expression
and NPY-induced insulin release would be necessary to
establish more directly the role of corticosterone in the
observed effects of ADX. However, such experiments can
provide differing results, depending on the type and
route of glucocorticoid replacement (24, 40). A recent
study has shown that icv infusion of dexamethasone for
3 days increases insulin levels in normal rats, which pro-
vides some evidence for a central effect of glucocorticoids
in controlling insulin release possibly through altering
NPY-regulated pathways (40).
It is also possible that glucocorticoids act by regulating
levels of corticotropin-releasing hormone (CRH), which
has been reported to significantly decrease food intake
(41), insulinemia (42), and inhibit the synthesis and
release of NPY (43). Although changes in CRH action
have not been linked to changes in Y1- and Y5-receptor
mRNA, the reduction in NPY action following ADX may
be a result of increased CRH activity as well as decreased
corticosterone levels. Recently, it has been shown that
ADX results in a similar, although not so marked, reduc-
tion in type 2 CRH-receptor (CRHR2) mRNA levels with-
in the VMH, without any change in levels within the PVN
(44). It is noteworthy that the specific reduction in VMH
CRHR2 mRNA in these rats was also associated with a
decreased body weight and decreased basal plasma
insulin and leptin levels. However, the exact roles of these
receptors within the VMH are far from understood.
Enhanced NPY expression in the VMH is associated
with the obesity syndrome (45). Furthermore, NPY has
been shown to directly inhibit over one fifth of spon-
taneously active rat VMH neurons, and this inhibition
is potentiated by overfeeding (46). Therefore, the mech-
anism by which acute icv NPY stimulates insulin
release in the absence of feeding may be by inhibiting
the spontaneous activity of the VMH through Y1 and
Y5 receptors. A reduction of these receptors with ADX
would then reduce the ability of NPY to inhibit VMH
neurons. In agreement with others, we found that acute
icv NPY administration had no affect on plasma glu-
cose levels, indicating that NPY-induced insulin release
is not simply a secondary response to changes in
peripheral glucose (47). By associating the decreased
basal insulin levels and lack of insulin release in
response to NPY injection in ADX rats with downreg-
ulation of Y1-and Y5-receptor mRNA in the VMH, our
study highlights a role for Y1-and Y5-receptors in the
VMH in the etiology of NPY-induced hyperinsuline-
mia, insulin resistance, and obesity.
In summary, acute NPY-stimulated insulin release
was blocked by ADX, an effect that coincided with
selective reduction in Y1- and Y5-receptor mRNA-
expressing neurons in the VMH. These data suggest
that glucocorticoids are necessary for acute NPY-stim-
ulated insulin release and indicates that the mecha-
nisms of action for this effect of NPY involves the Y1
and Y5 receptors in the VMH.
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